(3-006) Examining Adverse Effects Reported to the FDA on Glucagon-Like Peptide-1 Receptor Agonists and Glucagon-Like Peptide-1/Glucose-Dependent Insulinotropic Polypeptide Receptor Agonists
Monday, December 9, 2024
12:00 PM – 1:00 PM
Location: Hall G, Lower Level
Category: Evaluative Study Topic: Drug Information/Drug Use Evaluation